The DOI matches its Crossref record.
Insulin-like growth factor I and its binding proteins in the cardiovascular system
Abstract
A large body of evidence has conclusively shown that IGF I is an essential regulator of developmental growth. Thus mice bearing a null mutation for the IGF IR gene invariably die shortly after birth, and mice bearing a null mutation for the IGF I gene have a high neonatal mortality rate and marked growth retardation [158,159]. The ubiquitous effects of IGF I make it likely that this autocrine/endocrine system plays an important role in cardiovascular development. Its potential role in cardiovascular pathophysiology has raised considerable interest over the last several years. There is strong evidence that IGF I is a critical determinant of vascular growth responses in vitro and in vivo. Regulation of VSMC IGF IR availability appears to be crucial for the control of VSMC growth, and as such is at a convergence point for the effects of multiple growth factors. Clinical studies relating to IGF I in hypertension are extremely limited but significant data from animal studies now suggest a role for IGF I as a mediator of hypertrophic/hyperplastic responses in hypertension. Furthermore, significant animal data now exist implicating IGF I as an important mediator of cardiac hypertrophic responses. The development of a specific pharmacologic inhibitor of the IGF IR should allow rational clinical trials to address the function of IGF I as a mediator of cardiovascular growth responses. Specifically, areas of great interest will include the potential prevention of post-angioplasty restenosis, of atherosclerotic lesion development and progression, and of the complications of hypertensive vascular disease. The use of IGF I to ameliorate myocardial growth and function post infarction, to promote angiogenesis and collateral artery formation in the setting of peripheral vascular disease, are other important directions for future research. The use of IGF I to improve wound healing, improve recovery from acute renal failure and improve glucose control is currently under investigation. Clearly ongoing studies addressing the mechanisms whereby IGF I interacts with its receptor and binding proteins to produce its effects in cardiovascular tissues, will provide a rationale for novel and pertinent clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels
Delafontaine, P., Song, Y.-H., & Li, Y. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000105902.89459.09 · Cited by 542
Self-citationThe Insulin-Like Growth Factor Axis: A Review of Atherosclerosis and Restenosis
Bayes-Genis, A., Conover, C. A., & Schwartz, R. S. (2000) · Circulation Research · doi:10.1161/01.res.86.2.125 · Cited by 416
Colao, A., Marzullo, P., Di Somma, C., & Lombardi, G. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01218.x · Cited by 388
Sonntag, W. E., Lynch, C. D., Cooney, P. T., & Hutchins, P. M. (1997) · Endocrinology · doi:10.1210/endo.138.8.5330 · Cited by 307
Metadata
- Authors
- DELAFONTAINE, P.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-12
- Volume
- 30
- Issue
- 6
- Pages
- 825-834
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2002120032
- Cited by
- 216
- References
- 0
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-like growth factor I and its binding proteins in the cardiovascular system. https://app.cochat.ai/papers/10.1016/0008-6363(95)00163-8
- The paper
- DELAFONTAINE, P. (1995). Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovascular Research. https://doi.org/10.1016/0008-6363(95)00163-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.